Invention Grant
- Patent Title: Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
-
Application No.: US13558312Application Date: 2012-07-25
-
Publication No.: US09890207B2Publication Date: 2018-02-13
- Inventor: Ron Diskin , Pamela J. Bjorkman , Michel Nussenzweig , Johannes Scheid
- Applicant: Ron Diskin , Pamela J. Bjorkman , Michel Nussenzweig , Johannes Scheid
- Applicant Address: US CA Pasadena US NY New York
- Assignee: California Institute of Technology,The Rockefeller University
- Current Assignee: California Institute of Technology,The Rockefeller University
- Current Assignee Address: US CA Pasadena US NY New York
- Agency: Lewis Roca Rothgerber Christie LLP
- Main IPC: C07K16/10
- IPC: C07K16/10
Abstract:
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
Public/Granted literature
- US20120288502A1 COMPOSITIONS AND METHODS FOR IMPROVING POTENCY AND BREADTH OF HIV ANTIBODIES Public/Granted day:2012-11-15
Information query
